SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 12.3% Stake in Astria Therapeutics

FMR LLC and its affiliates, including Abigail P. Johnson, have reported a beneficial ownership of 12.3% of Astria Therapeutics, Inc.'s Common Stock as of March 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson, as reporting persons, collectively beneficially own 6,936,766 shares of Astria Therapeutics, Inc. Common Stock.
• This ownership represents 12.3% of the total outstanding class of Astria Therapeutics, Inc. Common Stock.
• FMR LLC holds sole voting power over 6,934,053 shares and sole dispositive power over 6,936,766 shares.
• Abigail P. Johnson holds sole dispositive power over 6,936,766 shares.
• Warrants held by the reporting persons are not exercisable under current exercise limits and are therefore not included in the reported beneficial ownership.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• FMR LLC's subsidiaries, including FIAM LLC, Fidelity Institutional Asset Management Trust Company, and Fidelity Management & Research Company LLC, are identified as relevant entities, with Fidelity Management & Research Company LLC beneficially owning 5% or greater of the outstanding shares.
• Abigail P. Johnson is a Director, Chairman, and Chief Executive Officer of FMR LLC, and a member of the Johnson family who are predominant owners of FMR LLC's Series B voting common shares.

Sentiment

Score: 5

Explanation: The document is a factual report of beneficial ownership and does not contain information that would inherently suggest positive or negative sentiment regarding the company's performance or outlook. It is a neutral disclosure of an investment position.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of a significant institutional ownership stake in a biotechnology company. Large institutional holdings like this are common in the biotech sector, where long-term investment in promising therapies is typical. The disclosure by FMR LLC, a major asset manager, indicates continued investment interest in Astria Therapeutics.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by FMR LLC and Abigail P. Johnson may be viewed positively by other shareholders, indicating confidence from a major investor. It also provides transparency regarding the ownership structure.

Key Dates

Keywords

Astria Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Biotechnology, Pharmaceuticals